Project Grant R15CA290481
Award Date
8/5/24
Completion Date
7/31/27
Dollars Obligated
$500K
Federal Agency
National Cancer Institute
Awardee
Rowan University (DMDEQP66JL85)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Camden, NJ 08103, USA
Similar Awards
This $491,357 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research at Case Western Reserve University to investigate a novel approach for treating acute myeloid leukemia (AML). The key objectives are to study the mechanisms by which a small molecule that activates the mTORC1 signaling pathway can sensitize AML cells to proteasome inhibitor drugs, leading to mitochondrial damage and reversal of drug resistance. The researchers...
This $674,440 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Biology Research (CFDA 93.396) federal grant program. The grant supports research at the University of Miami to comprehensively define the clinical impact of myeloma-defining genomic and immune events among myeloma precursor conditions (MPCs), in order to differentiate benign from malignant MPCs. The study will utilize novel single-cell whole genome sequencing (scWGS) to characterize the subclonal...
This federal Project Grant award of $542,663 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by The University of Texas M.D. Anderson Cancer Center to investigate the role of BRG1/BRM-targeting ATPases in the treatment of acute myeloid leukemia (AML). The key objectives are to: 1) Determine the preclinical efficacy of BRG1/BRM antagonists, such as the inhibitor FHD-286 and the degrader AU15330, and associated epigenomic and transcriptomic changes in...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) provides $344,111 to Loyola University of Chicago's Health Sciences Campus to conduct research on targeting panoptotic pathways for the treatment of myelodysplastic syndromes (MDS). The key objectives are to determine whether genetic inactivation or pharmacological inhibition of RIPK1 and TBK1 can prevent MDS development, restore blood cell counts, and eliminate...
This $621,156 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Trustees of the University of Pennsylvania aims to identify novel regulators of endoplasmic reticulum (ER) homeostasis in malignant plasma cells that can be targeted to induce cell death or prevent upstream events fostering multiple myeloma (MM), a deadly plasma cell malignancy. The key objectives are to: 1) inhibit P2RX receptor signaling in premalignant and malignant...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $205,700.00 to the Sloan-Kettering Institute for Cancer Research to conduct research aimed at addressing the rapid development of resistance to targeted therapies for metastatic colorectal cancer. The research will evaluate how intrinsic tumor features modulate the development of resistance to targeted therapies, and test a novel combination approach of DNA repair inhibition and...
The National Cancer Institute awarded a $701,330 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Icahn School of Medicine at Mount Sinai. The grant supports research to develop selective inhibitors targeting the lysine methyltransferase SETD8 for the treatment of multiple myeloma, an incurable plasma cell malignancy. Key objectives include optimizing SETD8 inhibitor compounds into in vivo chemical probes, evaluating their efficacy in multiple myeloma cellular and...
This $238,722 federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research at the Sloan-Kettering Institute for Cancer Research to investigate the role of mutagenic DNA repair pathways in the persistence and acquired drug resistance of cancer cells. The key objectives are to: (1) study persistence mechanisms in BRCA1/2-mutant cancer cells treated with PARP inhibitors, (2) examine how mutagenic DNA repair via...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $606,993 to Emory University to conduct research aimed at improving immune modulation as a strategy to prevent the progression of smoldering multiple myeloma (SMM) to clinical multiple myeloma (MM). The key objectives are to: Evaluate whether properties of immune cells at baseline in SMM correlate with the risk of progression to clinical MM. Assess changes in circulating and...
The National Cancer Institute (NCI) awarded a $100,760 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research, a prominent non-profit cancer research organization located in New York, NY. The grant, running from January 1, 2025 to December 31, 2028, will fund research to develop a nanoparticle-based RNA interference (RNAi) therapy targeting the tumor immune microenvironment in multiple myeloma (MM). The project aims to...